Navigation Links
Natural compound shows promise against Huntington's disease
Date:11/15/2010

attention to Drosophila. In collaboration with J. Lawrence Marsh, Ph.D., a professor of developmental and cell biology at the University of California, Irvine, Maher tested fisetin in fruit flies overexpressing mutant huntingtin in neurons in the brain. The affected flies don't live as long as normal flies and also have defective eye development. When they were fed fisetin, however, the HD flies maintained their life span and had fewer eye defects.

Finally, Maher and her team tested fisetin's effects in a mouse model of HD. HD mice develop motor defects early on and have much shorter life spans than normal control animals. When Maher and her team fed them fisetin, the onset of the motor defects was delayed, and their life span was extended by about 30 percent.

"Fisetin was not able to reverse or stop the progress of the disease," Maher notes, "but the treated mice retained better motor function for longer, and they lived longer."

Fisetin, which also has anti-inflammatory properties and maintains levels of glutathione, a major cellular antioxidant that plays a key role in protecting against different types of stress in cells, has not yet been tested in humans. But Maher's findings suggest that the compound may be able to slow down the progression of Huntington's disease in humans and improve the quality of life for those who have it. While she cautions that it won't necessarily be effective for people already in the advanced stages of the disease, for those in the early stages or who are presymptomatic, fisetin might help.

Furthermore, once their safety and efficacy are proved in humans, the advent of substances like fisetin might prompt more people to be tested for the mutation. "Cells are damaged and dying before there are overt symptoms," Maher says. "If patients know they have the mutation, then they could potentially start treatment before they start showing symptoms, which might be more effective than waiting for the symptoms
'/>"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
854-534-100-1340
Salk Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Morrison Natural History Museum discovers baby sauropod tracks
2. NSF awards grants for research on coupled natural and human systems
3. TEEB report puts worlds natural assets on the global political radar
4. From bees to coral reefs: How humans impact partnerships in the natural world
5. Can naturally raised beef find its place in the industry?
6. Unlike us, honeybees naturally make quick switch in their biological clocks, says Hebrew University researcher
7. Veterinarian says natural foods not always best for pets
8. Artificial enzyme removes natural poison
9. Turning school ground natural areas into environmental labs
10. Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster
11. Thesis analyzes factors responsible for the case of Basque natural cider turning bitter
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Natural compound shows promise against Huntington's disease
(Date:8/28/2015)... 2015 According to a new ... Assessment Type (Pen & Paper Based, Hosted, Biometrics), Service, ... Academic Research), Vertical and Region - Global Forecast to ... to grow from USD 2.4 Billion in 2015 to ... Growth Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)...  Based on its recent analysis of the biometric products ... Biometrics Company of the Year Award. DERMALOG is the leading ... Africa . It has particularly gained prominence ... one of the largest biometric mass applications in the world, ... Bank of Nigeria with its biometric ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... down the biological trigger that gives rise to ... that can cause blindness and deafness. The findings ... lead to new treatments for osteoporosis and other ... Lawrence Livermore and Lawrence Berkeley national laboratories, the ...
... the common cold because there is scant evidence they ... the risks, according to a new systematic review of ... in the treatment of acute upper respiratory tract infections," ... the University of Auckland, New Zealand. "The implications for ...
... immunologists studying mast cells, known to play a central ... hormone-like molecule that can kill these cells by programming ... The findings move researchers another step closer to understanding ... researchers develop new treatments for allergy and inflammatory responses ...
Cached Biology News:Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3Doctors should stop prescribing antibiotics for the common cold, review advises 2VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease 2
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... 13 ,Exelixis, Inc. (Nasdaq: EXEL ) today announced ... common stock. The net proceeds of the,offering are approximately ... shares in the offering are being sold by,Exelixis. Exelixis ... up to an additional 1,050,000 shares of common stock. ...
... PITTSBURGH, Sept. 13 The Pittsburgh Life ... region,s life,sciences industry on a fast track ... and Chief Executive Officer, Renal Solutions, Inc., ... Initiatives, UPMC, John,L. Miclot, President and Chief ...
... September 13 In order,to meet its obligations under ... ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) is,publishing today ... June 2007,in accordance with International Financial Reporting Standards (IFRS). ... 2007, Shire announced its results in,respect of the same ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 2The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 3IFRS Information - First Half of 2007 2IFRS Information - First Half of 2007 3IFRS Information - First Half of 2007 4IFRS Information - First Half of 2007 5IFRS Information - First Half of 2007 6IFRS Information - First Half of 2007 7IFRS Information - First Half of 2007 8IFRS Information - First Half of 2007 9IFRS Information - First Half of 2007 10IFRS Information - First Half of 2007 11IFRS Information - First Half of 2007 12IFRS Information - First Half of 2007 13IFRS Information - First Half of 2007 14IFRS Information - First Half of 2007 15IFRS Information - First Half of 2007 16IFRS Information - First Half of 2007 17IFRS Information - First Half of 2007 18IFRS Information - First Half of 2007 19IFRS Information - First Half of 2007 20IFRS Information - First Half of 2007 21IFRS Information - First Half of 2007 22IFRS Information - First Half of 2007 23IFRS Information - First Half of 2007 24IFRS Information - First Half of 2007 25IFRS Information - First Half of 2007 26IFRS Information - First Half of 2007 27IFRS Information - First Half of 2007 28IFRS Information - First Half of 2007 29IFRS Information - First Half of 2007 30IFRS Information - First Half of 2007 31IFRS Information - First Half of 2007 32IFRS Information - First Half of 2007 33
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
... ,human IgG subclass 1 100% ,human IgG subclass ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... 0.04% ,human IgG Fab ...
...
Biology Products: